All Oncology News

Puxitatug samrotecan demonstrated preliminary efficacy and manageable safety in advanced or metastatic endometrial cancer.

Luveltamab tazevibulin was active and safe in patients with platinum-resistant ovarian cancer and a FRα expression of at least 25%.

BVAC-C was effective with a manageable safety profile when combined with durvalumab in patients with recurrent HPV-positive cervical cancer.

Mirvetuximab soravtansine continued to showcase superior OS, PFS, ORR, & DOR benefits over chemotherapy in FRα-positive platinum-resistant ovarian cancer.

Patients with cyclin E1–positive platinum-resistant ovarian cancer experienced a greater response to azenosertib vs the overall DENALI population.

The combination of avutometinib and defactinib has previously shown activity in patients with low-grade serous ovarian cancer.

The KEYLYNK-001 trial found improved PFS among patients with advanced ovarian cancer given pembrolizumab/olaparib.

The combination of zimberelimab and lenvatinib had antitumor activity and a manageable safety profile in pretreated advanced cervical cancer.

Afuresertib combined with paclitaxel did not elicit PFS or OS benefits vs paclitaxel alone in patients with unselected platinum-resistant ovarian cancer.

Olaparib maintenance following durvalumab plus chemotherapy improved PFS in different subgroups of pMMR endometrial cancer.

The addition of pembrolizumab to chemoradiotherapy prolonged survival and time to second progression in patients with locally advanced cervical cancer.

Cadonilimab plus lenvatinib showed promise as therapy for patients with advanced endometrial cancer and disease progression on prior platinum therapy.

Nivolumab elicited PR/CRs in all patients treated with resectable dMMR endometrial cancer and no patients experienced disease recurrence during follow-up.

Vepdegestrant boosts PFS in select ESR1-mutated breast cancer, maintenance OSE2101 combination provides survival benefit in PDAC, and more from OncLive.

Patients with relapsed/refractory MCL who opted for elective treatment interruptions from venetoclax/ibrutinib experienced durable responses.

Retifanlimab demonstrated durable activity with a tolerable safety profile in patients with chemotherapy-naive MCC.

Megan Melody, MD, discusses how embracing authenticity, building patient trust, and supporting fellow female oncologists are key to thriving in the field.

A discovery by researchers from Mayo Clinic may help explain why immunotherapy hasn't been helpful for many patients with metastatic colorectal cancer.

The European Commission has approved liso-cel in relapsed/refractory follicular lymphoma after at least 2 prior lines of systemic therapy.

Micro-array needles containing doxorubicin displayed safety and early activity in basal cell carcinoma of the skin.

All the data on the tumor-agnostic approvals of T-DXd and repotrectinib are featured in this article and it's downloadable PDF visual pages!

AVA6000 showed early efficacy and safety signals in previously treated, locally advanced or metastatic salivary gland cancers.

Renier Brentjens, MD, PhD, details solid tumors his laboratory is investigating CAR T-cell therapy in and ways to mitigate on-target, off-tumor toxicities.

Acalabrutinib with venetoclax and obinutuzumab was effective and well tolerated in treatment-naive CLL harboring a TP53 aberration.

Neal D. Shore, MD, FACS, discusses the evaluation of nadofaragene firadenovec in intermediate-risk NMIBC and its potential effect on treatment strategies.

Single-agent mosunetuzumab generated response rates in patients with relapsed/refractory MCL who previously received a BTK inhibitor.

Roswell Park Comprehensive Cancer Center’s Intensive Care Unit has earned the Beacon Award for Excellence from the AACN.

A BLA has been accepted in China seeking the approval of tisotumab vedotin for metastatic cervical cancer that has progressed on or after systemic therapy.

177Lu rhPSMA-10.1 injection led to proportionally higher absorbed radiation doses in tumors vs healthy tissues in patients with mCRPC.

Palbociclib plus letrozole prolonged PFS compared with placebo plus letrozole in patients with ER-positive advanced endometrial cancer.